Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial
2017· article· en· Journal of Alzheimer s Disease· Neuroscience
aboutno aff
332
citations
Works
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.
Route
Field
Type
Language
Year range
to
Screen consensus
Sort
Flags
Screening evidence
Direct labels are sparse and unvalidated. Missing labels are unknown.
1 filter active
59 workspage 1 of 3
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)
2017· article· en· Diabetes Care· Medicine
aff
177
citations
A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
2010· article· en· Diabetes Care· Medicine
aff
158
citations
Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes
2007· article· en· Diabetic Medicine· Medicine
aff
148
citations
Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis
2014· review· en· BMJ· Medicine
afffund
117
citations
Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice
2012· article· en· Diabetes Obesity and Metabolism· Medicine
aff
114
citations
Evidence-Informed Guidelines for Treating Frail Older Adults With Type 2 Diabetes: From the Diabetes Care Program of Nova Scotia (DCPNS) and the Palliative and Therapeutic Harmonization (PATH) Program
2013· article· en· Journal of the American Medical Directors Association· Medicine
affaboutno abstract
98
citations
Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies
2016· review· en· Diabetes Care· Biochemistry, Genetics and Molecular Biology
afffund
70
citations
Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
2019· article· en· Diabetes Therapy· Medicine
aff
65
citations
Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes
2017· review· en· Clinical Epidemiology· Medicine
affabout
52
citations
Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different
2019· review· en· Advances in Therapy· Medicine
afffund
52
citations
The safety and efficacy of adding once‐daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries
2012· article· en· Diabetes Obesity and Metabolism· Medicine
aff
51
citations
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial
2023· article· en· The Lancet Diabetes & Endocrinology· Medicine
affno abstract
49
citations
44
citations
Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin
2008· article· en· Diabetes Research and Clinical Practice· Medicine
fundno affno abstract
35
citations
A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus
2017· review· en· Clinical Therapeutics· Medicine
affno abstract
24
citations
Flexibly timed once‐daily dosing with degludec: a new ultra‐long‐acting basal insulin
2013· review· en· Diabetes Obesity and Metabolism· Medicine
afffund
23
citations
Role of omalizumab in insulin hypersensitivity: a case report and review of the literature
2018· review· en· Diabetic Medicine· Medicine
aff
19
citations
18
citations
Comparison of insulin lispro protamine suspension and insulin detemir in basal‐bolus therapy in patients with Type 1 diabetes
2010· article· en· Diabetic Medicine· Medicine
aff
17
citations
Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand
2016· article· en· Applied Health Economics and Health Policy· Medicine
affno abstract
16
citations
Observational Study of Once-Daily Insulin Detemir in People with Type 2 Diabetes Aged 75 Years or Older
2013· article· en· Drugs & Aging· Medicine
aff
16
citations
Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis
2011· review· en· Journal of Medical Economics· Medicine
affabout
15
citations
Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating β-catenin and CREB activities
2012· article· en· American Journal of Physiology-Endocrinology and Metabolism· Medicine
afffund
11
citations
Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective
2017· article· en· Journal of Medical Economics· Medicine
aff
10
citations